Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming to Promote Cell Survival

Brett M. Noel, Steven B. Ouellette, Laura Marholz, Deborah M Dickey, Connor Navis, Tzu-Yi Yang, Vinh Nguyen, Sarah J. Parker, David A Bernlohr, Zohar Sachs, Laurie L Parker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Resistance to chemotherapy can occur through a wide variety of mechanisms. Resistance to tyrosine kinase inhibitors (TKIs) often arises from kinase mutations - however, "off-target" resistance occurs but is poorly understood. Previously, we established cell line resistance models for three TKIs used in chronic myeloid leukemia treatment, and found that resistance was not attributed entirely to failure of kinase inhibition. Here, we performed global, integrated proteomic and transcriptomic profiling of these cell lines to describe mechanisms of resistance at the protein and gene expression level. We used whole transcriptome sequencing and SWATH-based data-independent acquisition mass spectrometry (DIA-MS), which does not require isotopic labels and provides quantitative measurements of proteins in a comprehensive, unbiased fashion. The proteomic and transcriptional data were correlated to generate an integrated understanding of the gene expression and protein alterations associated with TKI resistance. We defined mechanisms of resistance and two novel markers, CA1 and alpha-synuclein, that were common to all TKIs tested. Resistance to all of the TKIs was associated with oxidative stress responses, hypoxia signatures, and apparent metabolic reprogramming of the cells. Metabolite profiling and glucose-dependence experiments showed that resistant cells had routed their metabolism through glycolysis (particularly through the pentose phosphate pathway) and exhibited disruptions in mitochondrial metabolism. These experiments are the first to report a global, integrated proteomic, transcriptomic, and metabolic analysis of TKI resistance. These data suggest that although the mechanisms are complex, targeting metabolic pathways along with TKI treatment may overcome pan-TKI resistance.

Original languageEnglish (US)
Pages (from-to)1842-1856
Number of pages15
JournalJournal of Proteome Research
Volume18
Issue number4
DOIs
StatePublished - Apr 5 2019

Fingerprint

K562 Cells
Protein-Tyrosine Kinases
Cell Survival
Cells
Proteomics
Metabolism
Gene expression
Phosphotransferases
Pentoses
Gene Expression
Cell Line
Pentose Phosphate Pathway
alpha-Synuclein
Proteins
Oxidative stress
Chemotherapy
Glycolysis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Metabolites
Metabolic Networks and Pathways

Keywords

  • chronic myeloid leukemia
  • metabolic reprogramming
  • metabolite profiling
  • tyrosine kinase inhibitors

PubMed: MeSH publication types

  • Journal Article

Cite this

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming to Promote Cell Survival. / Noel, Brett M.; Ouellette, Steven B.; Marholz, Laura; Dickey, Deborah M; Navis, Connor; Yang, Tzu-Yi; Nguyen, Vinh; Parker, Sarah J.; Bernlohr, David A; Sachs, Zohar; Parker, Laurie L.

In: Journal of Proteome Research, Vol. 18, No. 4, 05.04.2019, p. 1842-1856.

Research output: Contribution to journalArticle

@article{ff9c9622608640d1a86c3689c4e26fe7,
title = "Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming to Promote Cell Survival",
abstract = "Resistance to chemotherapy can occur through a wide variety of mechanisms. Resistance to tyrosine kinase inhibitors (TKIs) often arises from kinase mutations - however, {"}off-target{"} resistance occurs but is poorly understood. Previously, we established cell line resistance models for three TKIs used in chronic myeloid leukemia treatment, and found that resistance was not attributed entirely to failure of kinase inhibition. Here, we performed global, integrated proteomic and transcriptomic profiling of these cell lines to describe mechanisms of resistance at the protein and gene expression level. We used whole transcriptome sequencing and SWATH-based data-independent acquisition mass spectrometry (DIA-MS), which does not require isotopic labels and provides quantitative measurements of proteins in a comprehensive, unbiased fashion. The proteomic and transcriptional data were correlated to generate an integrated understanding of the gene expression and protein alterations associated with TKI resistance. We defined mechanisms of resistance and two novel markers, CA1 and alpha-synuclein, that were common to all TKIs tested. Resistance to all of the TKIs was associated with oxidative stress responses, hypoxia signatures, and apparent metabolic reprogramming of the cells. Metabolite profiling and glucose-dependence experiments showed that resistant cells had routed their metabolism through glycolysis (particularly through the pentose phosphate pathway) and exhibited disruptions in mitochondrial metabolism. These experiments are the first to report a global, integrated proteomic, transcriptomic, and metabolic analysis of TKI resistance. These data suggest that although the mechanisms are complex, targeting metabolic pathways along with TKI treatment may overcome pan-TKI resistance.",
keywords = "chronic myeloid leukemia, metabolic reprogramming, metabolite profiling, tyrosine kinase inhibitors",
author = "Noel, {Brett M.} and Ouellette, {Steven B.} and Laura Marholz and Dickey, {Deborah M} and Connor Navis and Tzu-Yi Yang and Vinh Nguyen and Parker, {Sarah J.} and Bernlohr, {David A} and Zohar Sachs and Parker, {Laurie L}",
year = "2019",
month = "4",
day = "5",
doi = "10.1021/acs.jproteome.9b00028",
language = "English (US)",
volume = "18",
pages = "1842--1856",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming to Promote Cell Survival

AU - Noel, Brett M.

AU - Ouellette, Steven B.

AU - Marholz, Laura

AU - Dickey, Deborah M

AU - Navis, Connor

AU - Yang, Tzu-Yi

AU - Nguyen, Vinh

AU - Parker, Sarah J.

AU - Bernlohr, David A

AU - Sachs, Zohar

AU - Parker, Laurie L

PY - 2019/4/5

Y1 - 2019/4/5

N2 - Resistance to chemotherapy can occur through a wide variety of mechanisms. Resistance to tyrosine kinase inhibitors (TKIs) often arises from kinase mutations - however, "off-target" resistance occurs but is poorly understood. Previously, we established cell line resistance models for three TKIs used in chronic myeloid leukemia treatment, and found that resistance was not attributed entirely to failure of kinase inhibition. Here, we performed global, integrated proteomic and transcriptomic profiling of these cell lines to describe mechanisms of resistance at the protein and gene expression level. We used whole transcriptome sequencing and SWATH-based data-independent acquisition mass spectrometry (DIA-MS), which does not require isotopic labels and provides quantitative measurements of proteins in a comprehensive, unbiased fashion. The proteomic and transcriptional data were correlated to generate an integrated understanding of the gene expression and protein alterations associated with TKI resistance. We defined mechanisms of resistance and two novel markers, CA1 and alpha-synuclein, that were common to all TKIs tested. Resistance to all of the TKIs was associated with oxidative stress responses, hypoxia signatures, and apparent metabolic reprogramming of the cells. Metabolite profiling and glucose-dependence experiments showed that resistant cells had routed their metabolism through glycolysis (particularly through the pentose phosphate pathway) and exhibited disruptions in mitochondrial metabolism. These experiments are the first to report a global, integrated proteomic, transcriptomic, and metabolic analysis of TKI resistance. These data suggest that although the mechanisms are complex, targeting metabolic pathways along with TKI treatment may overcome pan-TKI resistance.

AB - Resistance to chemotherapy can occur through a wide variety of mechanisms. Resistance to tyrosine kinase inhibitors (TKIs) often arises from kinase mutations - however, "off-target" resistance occurs but is poorly understood. Previously, we established cell line resistance models for three TKIs used in chronic myeloid leukemia treatment, and found that resistance was not attributed entirely to failure of kinase inhibition. Here, we performed global, integrated proteomic and transcriptomic profiling of these cell lines to describe mechanisms of resistance at the protein and gene expression level. We used whole transcriptome sequencing and SWATH-based data-independent acquisition mass spectrometry (DIA-MS), which does not require isotopic labels and provides quantitative measurements of proteins in a comprehensive, unbiased fashion. The proteomic and transcriptional data were correlated to generate an integrated understanding of the gene expression and protein alterations associated with TKI resistance. We defined mechanisms of resistance and two novel markers, CA1 and alpha-synuclein, that were common to all TKIs tested. Resistance to all of the TKIs was associated with oxidative stress responses, hypoxia signatures, and apparent metabolic reprogramming of the cells. Metabolite profiling and glucose-dependence experiments showed that resistant cells had routed their metabolism through glycolysis (particularly through the pentose phosphate pathway) and exhibited disruptions in mitochondrial metabolism. These experiments are the first to report a global, integrated proteomic, transcriptomic, and metabolic analysis of TKI resistance. These data suggest that although the mechanisms are complex, targeting metabolic pathways along with TKI treatment may overcome pan-TKI resistance.

KW - chronic myeloid leukemia

KW - metabolic reprogramming

KW - metabolite profiling

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85062371502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062371502&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.9b00028

DO - 10.1021/acs.jproteome.9b00028

M3 - Article

C2 - 30730747

AN - SCOPUS:85062371502

VL - 18

SP - 1842

EP - 1856

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 4

ER -